Overview

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Status:
Completed
Trial end date:
2016-06-29
Target enrollment:
0
Participant gender:
All
Summary
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Ustekinumab
Criteria
Inclusion Criteria:

- patients with moderate to severe plaque type psoriasis for at least 6 months before
randomization

- patients eligible for systemic therapy with inadequately controlled psoriasis

Exclusion Criteria:

- forms of sporiasis other than plaque type psoriasis

- previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting
(IL)-17A or IL-17RA

Other protocol-defined inclusion/exclusion criteria may apply